This study is testing a new radioactive tracer called 11C-ARMI. A tracer is a special drug that attaches to chemicals in your body and lights up during imaging scans, helping doctors see them better. Researchers want to see how 11C-ARMI works in healthy people during a PET (positron emission tomography) scan, which is a type of imaging scan. They will be looking at how much of the tracer is taken up by your brain and body. This information could help them understand diseases like Alzheimer's and Parkinson's in the future. You can join if you are 18 or older and have been screened under specific NIMH protocols. The study aims to measure the distribution volume of the tracer in the brain. The current status of this study is unclear.

Study design

This is an interventional study planning to enroll 40 healthy participants. All participants will receive an injection of 11C-ARMI followed by a PET/CT scan.

What's involved

You will receive an intravenous (IV) injection of 11C-ARMI, followed by PET scanning.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, distribution volume, will be measured at 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.